Sökning: id:"swepub:oai:DiVA.org:uu-310948" >
Outcome of AL amylo...
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.
-
- Rosengren, Sara (författare)
- Uppsala universitet,Hematologi,University of Uppsala Hospital, Sweden
-
- Mellqvist, U-H (författare)
- South Elvsborg Hosp, Dept Hematol, Boras, Sweden,South Elvsborg Hospital, Sweden
-
- Nahi, H (författare)
- Karolinska Institutet,Karolinska Inst, Dept Hematol, Stockholm, Sweden
-
visa fler...
-
- Forsberg, K (författare)
- Norrlands Univ Hosp, Dept Hematol, Umeå, Sweden,Norrlands University Hospital, Sweden
-
- Lenhoff, S (författare)
- Skåne Univ Hosp, Dept Hematol, Lund, Sweden,Skåne University Hospital, Sweden
-
- Strömberg, O (författare)
- Karolinska Inst, Dept Hematol, Stockholm, Sweden,Karolinska Institute, Sweden
-
- Ahlberg, Lucia (författare)
- Linköping Univ Hosp, Dept Hematol, Linköping, Sweden,Region Östergötland, Hematologiska kliniken US
-
- Linder, O (författare)
- Örebro Univ Hosp, Dept Hematol, Örebro, Sweden,Örebro University Hospital, Sweden
-
- Carlson, Kristina (författare)
- Uppsala universitet,Hematologi,University of Uppsala Hospital, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2016-10-03
- 2016
- Engelska.
-
Ingår i: Bone Marrow Transplantation. - : Springer Science and Business Media LLC. - 0268-3369 .- 1476-5365. ; 51:12, s. 1569-1572
- Relaterad länk:
-
https://www.nature.c...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- High-dose melphalan and autologous stem cell transplantation (HDM/ASCT) is widely used in immunoglobulin light chain (AL) amyloidosis, but the benefit is debated mainly because of the high treatment-related mortality (24% in a randomised study comparing HDM/ASCT with oral melphalan/dexamethasone). We report here on the long-term outcome of all patients treated with HDM/ASCT for AL amyloidosis in Sweden between 1994 and 2009. Seventy-two patients were treated at eight Swedish centres. Median follow-up was 67.5 months. At least partial response (organ or haematological) was seen in 64% of the patients. Median overall survival was 98 months or 8.2 years, with 5-year survival 63.9% and 10-year survival 43.4%. In patients with cardiac involvement or multiple organ involvement, survival was significantly shorter, median overall survival 49 and 56 months, respectively. All mortality within 100 days from ASCT was 12.5% for all patients and 17.2% in the patients with cardiac involvement. For patients treated in the earlier time period (1994-2001), 100-day mortality was 23.8% compared with 7.8% in the later period (2002-2009). In conclusion, long survival times can be achieved in patients with AL amyloidosis treated with HDM/ASCT, also in smaller centres. Early mortality is high, but with a decreasing trend over time.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas